AQbD-guided development of a green RP-HPLC method for dual drug quantification in lipid–polymer hybrid nanoparticles for endometriosis therapy
This study developed a quality-by-design guided, green reversed-phase HPLC method for simultaneously quantifying two drugs within lipid-polymer hybrid nanoparticles designed for endometriosis treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (77)
- Angiogenesis and Endometriosis via openalex
- Antiangiogenesis Therapy for Endometriosis via openalex
- Applications of nanomaterials in endometriosis treatment via openalex
- Endometriosis: pathogenesis and treatment via openalex
- Inflammation and endometriosis via openalex
- Management of endometriosis-related infertility: Considerations and treatment options via openalex
- Mitigation of endometriosis using regenerative cerium oxide nanoparticles via openalex
- Nanoparticle-Assisted Combinatorial Therapy for Effective Treatment of Endometriosis via openalex
- Nanotechnologies for the detection and treatment of endometriosis via openalex
- Natural therapies assessment for the treatment of endometriosis via openalex
- Pathogenesis of Endometriosis: New Insights into Prospective Therapies via openalex
- Silibinin‐induced endoplasmic reticulum stress and mitochondrial dysfunction suppress growth of endometriotic lesions via openalex
- Silymarin amplifies apoptosis in ectopic endometrial tissue in rats with endometriosis; implication on growth factor GDNF, ERK1/2 and Bcl-6b expression via openalex
- Statins: Is it New Weaponry against Endometriosis? via openalex
- Synergistic and protective effect of atorvastatin and amygdalin against histopathological and biochemical alterations in Sprague-Dawley rats with experimental endometriosis via openalex
- The Main Theories on the Pathogenesis of Endometriosis via openalex
- W2950256303 via openalex
- W3035028232 via openalex
- W3037274725 via openalex
- W3043660947 via openalex
- W3088578015 via openalex
- W3112437689 via openalex
- W3123286810 via openalex
- W3147896862 via openalex
- W3155551263 via openalex
- W3160163680 via openalex
- W3165294846 via openalex
- W3181172479 via openalex
- W3199859397 via openalex
- W3202177173 via openalex
- W4224277899 via openalex
- W4280645308 via openalex
- W4281621957 via openalex
- W4281647867 via openalex
- W4281747404 via openalex
- W4283787196 via openalex
- W4303982385 via openalex
- W4304099265 via openalex
- W4313826570 via openalex
- W4317871409 via openalex
- W4360603804 via openalex
- W4379880222 via openalex
- W4381332445 via openalex
- W4384827416 via openalex
- W4385789578 via openalex
- W4386098432 via openalex
- W4386705206 via openalex
- W4387691764 via openalex
- W4399009666 via openalex
- W4399287142 via openalex
- W4400226084 via openalex
- W4400800854 via openalex
- W4400976580 via openalex
- W4401716129 via openalex
- W4401750643 via openalex
- W4403789232 via openalex
- W4406028519 via openalex
- W4408919746 via openalex
- W4409572028 via openalex
- W4412901634 via openalex
- W1965258535 via openalex
- W4414030846 via openalex
- W1969200311 via openalex
- W1969560715 via openalex
- W1984433905 via openalex
- W1992985052 via openalex
- W2006541788 via openalex
- W2010976109 via openalex
- W2014451654 via openalex
- W2029713923 via openalex
- W2044813154 via openalex
- W2051749006 via openalex
- W2132587402 via openalex
- W2589912397 via openalex
- W2754055756 via openalex
- W2886327465 via openalex
- W2905315184 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00